Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02019277
- Locations
- π¦πΊ
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
π¦πΊSt George Hospital; Cancer Care Centre, Kogarah, New South Wales, Australia
π¦πΊPort Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Participants
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO6864018Drug: Placebo
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02015715
- Locations
- πΈπ¬
Changi General Hospital; Clinical Trial & Research unit, Singapore, Singapore
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT02015676
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Phase 2
Completed
- Conditions
- Liver Cancer
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02013830
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Phase 2
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT02013817
- Locations
- π¦πΉ
LKH Hochsteiermark; Abt. fΓΌr Innere Medizin, Leoben, Austria
π¦πΉKh Der Barmherzigen Schwestern; Interne I X, Linz, Austria
π¦πΉA.Γ. Krankenhaus Der Elisabethinen Linz; I. Interne Abt., Linz, Austria
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02013219
- Locations
- πΊπΈ
Yale University School Of Medicine, New Haven, Connecticut, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
ππ°The Chinese University of Hong Kong, Shatin, Hong Kong
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02013206
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT02013765
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 285
- Registration Number
- NCT02011334
A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT02010216
Β© Copyright 2025. All Rights Reserved by MedPath